An Update on the Treatment of Hepatitis C

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "An Update on the Treatment of Hepatitis C"

Transcription

1 An Update on the Treatment of Hepatitis C Audrey Broyer, Pharm D, CGP Clinical Pharm acy Specialist Manchester VA Medical Center

2 Disclosure Statement I have no relevant financial relationships that would bias or compromise the presentation of these materials. Therapies not fully evaluated or approved by the FDA will be mentioned: Off-label recommendations supported by guidelines but not FDA approved

3 Objectives Discuss the pathophysiology and diagnosis of Hepatitis C virus Identify patients with chronic Hepatitis C virus that are appropriate for treatment Chose appropriate medication and duration of treatment for patient with Hepatitis C virus based on genotype, treatment history and other factors Provide education including potential side effects and drug interactions that are commonly encountered during Hepatitis C virus treatment

4 Chronic Hepatitis C Virus (HCV) 2.7 million people in the US Birth Cohort: higher risk Other risk factors Injection drug users Received clotting factor concentrates prior to 1987 Received blood transfusion or transplant prior to July 1992 Chronic hemodialysis People with HIV Transmission Injection drug users (#1) 30% of current users years old are infected, 70-90% of former users are infected Donated blood or blood products or organs (no longer common) Needlesticks Birth to HCV infected mother Sexual transmission is rare 15-25% of people clear the virus spontaneously Hepatitis C FAQs for Health Professionals. (Oct 14, 2015).

5 HCV Testing CDC. Testing for HCV infections. 2103

6 HCV Genotypes Messina JP, Humphreys I, Flaxman A, et al

7 Treatment Goal of treatment to reduce all-cause mortality and liver-related health adverse consequences, including end-stage liver disease and hepatocellular carcinoma, by the achievement of virologic cure.. Who to treat recommend treatment for all patients with chronic HCV infection, except those with short life expectancies that cannot be remediated by treating HCV, by transplantation, or by other directed therapy. Treatment regimen varies based on patient characteristics Genotype Liver health (cirrhotic or non-cirrhotic) Previous treatment Viral load AASLD/IDSA/IAS USA. Treatment Guidelines

8 Hepatitis C Medications 1980s Hepatitis C virus identified IntronA (interferon alfa 2b) approved Rebetron (interferon alfa 2b + ribavirin) approved, regimen of interferon 3x week + ribavirin mg/day for weeks 2001 pegylated interferon was approved 2011 first direct acting antivirals (DAA), Victrelis (boceprevir) and Incivek (telaprevir) approved in combination with PEG/RBV 2013 (Nov) Olysio (simeprevir) approved in combination with PEG/RBV 2013 (Dec) Sovaldi (sofosbuvir) approved in combination with PEG/RBV or RBV (first interferon free regimen) 2014 (Nov) Harvoni (ledipasvir/sofosbuvir) approved 2014 (Dec) Viekira Pak (ombitasvir/paritaprevir/ritonavir + dasabuvir) approved 2015 (July) - Technivie (ombitasvir/paritaprevir/ritonavir) and Daklinza (daclatasvir) approved Mandal A. Hepatitis C History. Updated April 26, Advances in Medications to Treat Hepatitis C. Updated September 2015.

9 Hepatitis C Online: Peginterferon alpha-2a Drug Summary Hepatitis C Online: Peginterferon alpha-2b Drug Summary Interferon Alpha Pegasys and PegIntron Mechanism of action not well understood Boosts immune response against hepatitis C virus Pegylated interferon has increased absorption and a longer half life Dosing Pegasys 180mcg subcutaneously weekly PegIntron 1.5mcg/kg subcutaneously weekly Dose adjustment for thrombocytopenia or neutropenia Adverse Drug Reactions - Flu-like symptoms, fatigue, depression, glucose dysregulation and thyroid dysfunction

10 Ribavirin Rebetrol, Copegus, Ribasphere Available in 200mg tablets, 200mg capsules, 40mg/mL oral solution Purine nucleoside analog mechanism of action against HCV is not understood Increases SVR rates Weight based dosing < 75kg: 1000mg per day 75kg: 1200mg per day Common Adverse Reactions hemolytic anemia, birth defects, rash, fatigue Hepatitis C Online: Ribavirin Drug Summary. 2015

11 Direct Acting Antiviral Agents Lam BP, Jeffers T, Younoszai Z, et al

12 Simeprevir (Olysio ) NS3/4A inhibitor Approved for Genotype 1 & 4 No longer recommended for genotype 4 Treatment of genotype 1 (with sofosbuvir) Dosing: 150mg once daily with food No adjustment for renal or hepatic impairment Screen patients with HCV genotype 1a infection for the presence of virus with the NS3 Q80K polymorphism Olysio [package insert]. Titusville, NJ: Jansen Therapeutics

13 Simeprevir (Olysio ) Precautions Not recommended in moderate-severe hepatic impairment (Child-Pugh B or C) Hepatic decompensation and failure have been reported Serious symptomatic bradycardia when administered with amiodarone Photosensitivity reactions Rash usually mild-moderate but can progress to severe Contains a sulfonamide moiety Adverse Reactions (from pooled Phase 3 trials) Simeprevir + Sofosbuvir Fatigue (25%), headache (21%), nausea (21%), insomnia (14%), pruritus (11%), rash (11%), photosensitivity (7%) Olysio [package insert]. Titusville, NJ: Jansen Therapeutics

14 Simeprevir Drug Interactions Substrate and mild inhibitor of CYP3A, P-glycoprotein (P-gp), and OATP1B1/3 Not Recommended Monitoring Recommended Dose Adjustment Recommended Amiodarone CCB Rosuvastatin (max 10mg) Anticonvulsants Antiarrhythmics Atorvastatin (max 40mg) Antifungals (azole) Digoxin PDE-5 inhibitors (not ED) Rifampin HIV medications St. John s Wort, Milk Thistle Cyclosporine Dexamethasone Midazolam Sirolimus Olysio [package insert]

15 Simeprevir & Sofosbuvir Clinical Trial COSMOS trial treatment naïve and null responders to PEG/RBV SVR 12 rates: Metavir Score 0-2 Metavir Score 3-4 Sim/Sof x12 Sim/Sof + RBV x12 Sim/Sof x24 Sim/Sof +RBV x24 13/14 (93%) 26/27 (96%) 14/15 (93%) 19/24 (79%) 13/14 (93%) 25/27 (93%) 16/16 (100%) 28/30 (93%) Lawitz E, et al. (2014). Lancet.

16 Simeprevir Counseling Prescribing info recommends storing in original container Janssen in house studies reported stable in open dish at room temperature for 2-5 weeks Take with food Phototoxicity use sunscreen, avoid tanning beds Take missed dose as soon as possible, but skip in < 12 hours until next dose Serious rash can occur, discuss with provider if rash occurs Many drug interactions, ask your health care provider or pharmacist prior to starting any new medications Olysio [package insert]

17 Sofosbuvir (Sovaldi ) Nucleotide polymerase NS5B inhibitor Treatment of Genotype 1, 2, 3, or 4 Dosing: 400mg once daily with or without food No dose adjustment Precautions Serious symptomatic bradycardia when administered with amiodarone Sovaldi [package insert]

18 Sofosbuvir (Sovaldi ) Most Common Adverse Reactions Sofosbuvir + RBV fatigue (30-38%), headache (24-30%), nausea (13-22%), insomnia (15-16%), anemia (6-10%), pruritus (11-27%), decreased appetite (6%) Sofosbuvir + PEG/RBV - fatigue (55-59%), headache (36-44%), nausea (29-34%), insomnia (25-29%), anemia (12-21%), pruritus (17%), decreased appetite (18%) Serious Adverse Reactions Pancytopenia (more common with PEG/RBV) Severe depression Sovaldi [package insert]

19 Sofosbuvir Drug Interactions Substrate of P-gp transporter and breast cancer resistance protein (BCRP) Drugs that induce P-gp in the intestine may result in decreased sofosbuvir plasma concentrations Not Recommended Amiodarone Anticonvulsants St. John s Wort HIV protease inhibitors Rifampin Sovaldi [package insert

20 Amiodarone Interaction Occurred when amiodarone was coadministed with sofosbuvir + investigational NS5A inhibitor, sofosbuvir + simeprevir, and ledipasvir/sofosbuvir Bradycardia and fatal cardiac arrest have been reported Bradycardia typically occurred within hours to days, but cases have been observed up to 2 weeks after initiating HCV treatment. Patients taking beta blockers, those with cardiac comorbidities or advanced liver disease are at increased risk. Cardiac monitoring in an in-patient setting for the first 48 hours of coadministration is recommended, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment. Patients who develop signs or symptoms of bradycardia should seek medical evaluation immediately. Symptoms may include near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pains, confusion or memory problems. Harvoni [package insert]

21 Sofosbuvir Clinical Trials Trial Patient Profile Regimen SVR 12 NEUTRINO N = 320 FISSION N = 499 POSITRON N = 278 FUSION N = 201 VALENCE N = 419 GT 1/4/5/6 Tx naïve GT 2/3 Tx naïve GT 2/3 Tx exp PEG ineligible GT 2/3 Tx exp GT 2/3 Tx naïve & Tx exp Sof + PEG/RBV x12 GT 1 89% (261/292) GT 1a 92% (206/225) GT 1b 82% (54/66) GT 4 96% (27/28) Sof + RBV x12 GT 2 95% (69/73) GT 3 56% (101/183) Sof + RBV x12 GT 2 93% (101/109) GT 3 61% (60/98) Sof + RBV x12 Sof + RBV x16 Sof + RBV x12 Sof + RBV x24 GT 2 82% (32/39) GT 3 30% (19/64) GT 2 89% (31/35) GT 3 62% (39/63) ( GT 2 93% (68/73) GT 3 84% (210/250) Sovaldi [package insert

22 Sofosbuvir Counseling Prescribing info recommends storing in original container Gilead stability studies Environment Container Acceptable Duration Room temp (77 o F) No container 45 days Direct sunlight No container 2-3 days Office lights No container 3 months Take with or without food Take missed dose as soon as you remember if the same day Many drug interactions, ask your health care provider or pharmacist prior to starting any new medications Avoid pregnancy if using with RBV Sovaldi [package insert

23 Ledipasvir/Sofosbuvir (Harvoni ) Approved for GT 1 (also for GT 3,4) Ledipasvir - a NS5A inhibitor Sofosbuvir - a nucleotide polymerase NS5B inhibitor Ledipasvir 90mg and Sofosbuvir 400mg Dosing - 1 tablet daily with or without food No dose adjustments Precautions Serious symptomatic bradycardia when administered with amiodarone Do not use with Sovaldi Common Adverse Reactions fatigue (13-18%), headache (11-17%), nausea (6-9%), diarrhea (3-7%), insomnia (3-6%) Harvoni [package insert]

24 Harvoni Drug Interactions Ledipasvir is an inhibitor of the P-gp transporters and BCRP May increase absorption of P-gp and BCRP substrates Ledipasvir and Sofosbuvir are substrates of P-gp transporter and BCRP P-gp and BCRP inhibitors may reduce plasma concentrations Not Recommended Amiodarone Anticonvulsants HIV Antiretrovirals Stribild Tipranivir/ritonavir St. John s Wort Simeprevir Rosuvastatin Rifampin Other Interactions Acid reducing agents* Digoxin HIV Antiretrovirals Atripla Tenofovir + HIV protease inhibitor Harvoni [package insert]

25 Harvoni Clinical Trials Trial Patient Profile Regimen SVR 12 (all pts) SVR 12 (cirrhotic) ION-1 N = 865 GT 1 Tx naïve LDV/SOF x12 LDV/SOF + RBV x12 LDV/SOF x24 LDV/SOF + RBV x24 99% (211/214) 97% (211/217) 98% (212/217 99% (215/217 94% (32/34) 100% (33/33) 94% (31/33) 100% (36/36) ION-2 N = 440 GT 1 Tx exp LDV/SOF x12 LDV/SOF + RBV x12 LDV/SOF x24 LDV/SOF + RBV x24 94% (102/109) 96% (107/111) 99% (108/109) 99% (110/111) 86% (19/22) 82% (19/22) 100% 22/22) 100% (22/22) ION-3 N = 647 GT 1 Tx naive LDV/SOF x8 HCV RNA < 6 mil HCV RNA 6 mil LDV/SOF + RBV x8 LDV/SOF x12 HCV RNA < 6 mil HCV RNA 6 mil 94% (202/215) 98% (121/123) 90% (83/92) 93% (201/216) 95% (206/216) 98% (129/131) 99% (84/85) Harvoni [package insert]

26 Harvoni Counseling Prescribing info recommends storing in original container Gilead stability studies Environment Container Acceptable Duration Room temp (77 o F) No container 45 days Direct sunlight No container 2-3 days Office lights No container 3 months Take with or without food Take missed dose as soon as you remember if the same day Many drug interactions, ask your health care provider or pharmacist prior to starting any new medications Avoid pregnancy if using with RBV Harvoni [package insert]

27 Ombitasvir/Paritaprevir/Ritona vir & Dasabuvir (Viekira Pak ) Genotype 1 (with or without RBV) Tab #1 2 tabs AM Ombitasvir (12.5mg) NS5A inhibitor Paritaprevir (75mg) NS3/4A protease inhibitor Ritonavir (50mg) CYP3A inhibitor Tab #2 1 tab AM & 1 tab PM (w/meal) Dasabuvir (250mg) - non-nucleoside NS5B polymerase inhibitor No dose adjustments Common Adverse Reactions fatigue (34%), nausea (22%), pruritus (18%), skin reactions (16%), insomnia (14%), asthenia (14%) Viekira Pak [package insert]

28 Ombitasvir/Paritaprevir/Ritona vir (Technivie ) Genotype 4 (with RBV) Non-cirrhotic only Same as tablet #1 in Viekira Pak Dasabuvir has no effect in GT 4 Dosing 2 Tabs AM with food Technivie [package insert]

29 Viekira Pak Contraindicated Moderate Severe hepatic impairment (Child-Pugh B or C) Substrates of CYP3A Moderate-Strong inducers of CYP3A Precautions Risk of hepatic decompensation and failure (increased w/ cirrhosis) ALT elevations (esp. w/ ethinyl estradiol) Risk of HIV protease inhibitor resistance (ritonavir) Many drug interactions Viekira Pak [package insert]. 2015

30 Viekira Pak Drug Interactions Paritaprevir: Inhibits UGT1, OATP1B1, OATP1B3, BCRP Metabolized by CYP3A Substrate of P-gp, BCRP, OATP1B1, OATP1B3 Ombitasvir: Inhibits UGT1 Metabolized by amide hydrolysis Substrate of P-gp, BCRP Ritonavir: Inhibits CYP3A4, BCRP Metabolized by CYP3A Substrate of P-gp Dasabuvir: Inhibits UGT1, BCRP Metabolized by CYP2C8 Substrate of P-gp, BCRP Viekira Pak [package insert] Contraindicated Alfuosin Gemfibrozil Rifampin Carbamazepine Phenytoin Phenobarbital Ergot. derivatives Ethinyl Estradiol St. John s Wort Lovastatin Simvastatin Pimozide Efavirenz Sildenafil (for PAH) Midazolam Triazolam Not Recommended Voriconazole Darunavir/Ritonavir Lopinavir/Ritonavir Rilpivirine Salmeterol Fluticasone Dose Adjustment Quetiapine (1/6 dose) Ketoconazole (max 200mg) Rosuvastatin (max 10mg) Pravastatin (max 40mg) Monitoring Suboxone Alprazolam Furosemide Amlodipine

31 Viekira Pak & Technivie Clinical Trials Trial Patient Profile Regimen SVR 12 SAPPHIRE-I N = 631 SAPPHIRE-II N = 394 PEARL-I N = 135 PEARL-II N = 179 PEARL-III N = 419 PEARL-IV N = 305 TURQUOISE-II N = 380 GT 1a/1b; Tx naïve Non-cirrhotic GT 1a/1b; Tx exp Non-cirrhotic GT 4, Tx naïve & exp Non-cirrhotic GT 1b; Tx exp Non-cirrhotic GT 1b; Tx naïve Non-cirrhotic GT 1a; Tx naïve Non-cirrhotic GT 1a/1b; Tx naïve Cirrhotic Viekira + RBV x12 96% ( ) Viekira + RBV x12 96% (166/173) Technivie +RBV x12 Technivie x12 Tx naïve 100% (42/42) Tx exp 100% (49/49) Tx naïve 91% (40/44) Viekira + RBV x12 100% (91/91) Viekira x12 100% (209/209) Viekira + RBV x12 97% (97/100) Viekira + RBV x12 Viekira + RBV x24 Viekira Pak [package insert]. 2015, Technivie [package insert] GT 1a 89% (124/140) GT 1b 99% (67/68) GT1a 95% (115/121)

32 Viekira Pak Counseling Store at room temperature (<86 o F) Take with a meal Monitor for signs of hepatic decompensation and failure Avoid pregnancy if using with RBV Missed doses: Ombitasvir/paritaprevir/ritonavir tablet Take as soon as you remember if <12 hours since your missed dose, if >12 hours then skip the missed dose Dasabuvir tablet Take as soon as you remember if <6 hours since your missed dose, if >6 hours then skip the missed dose Many drug interactions, ask your health care provider or pharmacist prior to starting any new medications Viekira Pak [package insert]

33 Daclatasvir (Daklinza ) Approved for GT 3 (with sofosbuvir) Available in 30mg and 60mg tablets NS5A inhibitor Dosing 60mg once daily with or without food Dose adjustment Drug interactions reduce to 30mg daily w/ strong CYP3A inhibitor and increase to 90mg w/ moderate CYP3A inducer Renal/Hepatic no dose adjustments Common Adverse Reactions headache (14%), fatigue (14%), nausea (8%), diarrhea (5%) Daklinza [package insert]

34 Daclatasvir Drug Interactions Substrate of CYP3A Inhibitor of P-gp OATP1BI and OATP1B3, BCRP Contraindicated Dose Adjustment ( 30mg) Strong CYP3A Inhibitors Dose Adjustment ( 90mg) Mod CYP3A Inducers Monitor Phenytoin Atazanavir/Ritonavir Dexamethasone Digoxin (reduce digoxin) Carbamazepine Clarithromycin Efavirenz Dabigatran Rifampin Ketoconazole Modafinil Statins St. John s wort Nefazodone Nafcillin Voriconazole Daklinza [package insert]

35 Daclatasvir Clinical Trials ALLY-3 Trial N = 152 Daclatasvir + Sofosbuvir x12 wk Patient Profile Tx naïve SVR 12 Tx exp SVR 12 All patients GT 3 All patients GT 3 Non-cirrhotic GT 3 Cirrhotic 90% (91/101) 86% (44/51) 89% (135/152) 98% (80/82) 92% (35/38) 96% (115/120) 58% (11/19) 69% (9/13) 63% (20/32) Daklinza [package insert]

36 Daclatasvir Counseling Store at room temperature between o F Take with or without food If you miss a dose take it as soon as you remember the same day Avoid pregnancy if using with RBV Many drug interactions, ask your health care provider or pharmacist prior to starting any new medications Daklinza [package insert]

37 Treatment Guidelines - Ratings American Association for the Study of Liver Diseases (AASLD) & Infectious Diseases Society of America (IDSA) & International Antiviral Society - USA Rating System Used to Rate the Level of the Evidence and Strength of the Recommendation for Each Recommendation Classification Class I Class II Class IIa Class IIb Class III Description Conditions for which there is evidence and/or general agreement that a given diagnostic evaluation, procedure, or treatment is beneficial, useful, and effective Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness and efficacy of a diagnostic evaluation, procedure, or treatment Weight of evidence and/or opinion is in favor of usefulness and efficacy Usefulness and efficacy are less well established by evidence and/or opinion Conditions for which there is evidence and/or general agreement that a diagnostic evaluation, procedure, or treatment is not useful and effective or if it in some cases may be harmful Level of Evidence Description Level A Data derived from multiple randomized clinical trials, meta-analyses, or equivalent Level B Level C Data derived from a single randomized trial, nonrandomized studies, or equivalent Consensus opinion of experts, case studies, or standard of care AASLD/IDSA/IAS USA. Treatment Guidelines

38 Treatment Recommendations GT 1, Tx Naïve Genotype Tx History Cirrhosis Regimen x Weeks Rating 1a Naïve Non-cirrhotic Harvoni x12 Viekira + RBV x12 Sim/Sof +/- RBV x12 Daclat/Sof x12 1b Naïve Non-cirrhotic Harvoni x12 Viekira x12 Sim/Sof +/- RBV x12 Daclat/Sof x12 1a Naïve Cirrhotic Harvoni x12 Viekira + RBV x24 Sim/Sof +/- RBV x24 Q80k Daclat/Sof +/-RBV x24 1b Naïve Cirrhotic Harvoni x12 Viekira x12 Sim/Sof +/- RBV x24 Daclat/Sof +/- RBV x24 1B 1B 1B 2B 1B 2aB AASLD/IDSA/IAS USA. Treatment Guidelines

39 Treatment Recommendations GT 1, Tx Experienced (PEG/RBV) Genotype Tx Hx Cirrhosis Regimen x Weeks Rating 1a Exp (PEG/RBV) Non-cirrhotic Harvoni x12 Viekira + RBV x12 Sim/Sof x12 Daclat/Sof x12 1b Exp (PEG/RBV) Non-cirrhotic Harvoni x12 Viekira x12 Sim/Sof x12 Daclat/Sof x12 1a Exp (PEG/RBV) Cirrhotic Harvoni x24 Harvoni + RBV x12 Viekira + RBV x24 Sim/Sof +/- RBV x24 (neg Q80K) Daclat/Sof +/- RBV x24 1b Exp (PEG/RBV) Cirrhotic Harvoni x24 Harvoni + RBV x12 Viekira x12 Sim/Sof +/- RBV x24 Daclat/Sof +/- RBV x24 AASLD/IDSA/IAS USA. Treatment Guidelines aB 2aB 2aB 1B 2aB 2aB 1B 2aB 2aB

40 Recommendations GT 1, Tx Experienced (DAA) Genotype Tx History Cirrhosis Regimen x Weeks Rating 1a Exp (Sof/RBV) Non-cirrhotic Harvoni x12 2bC 1b Exp (Sof/RBV) Cirrhotic Harvoni + RBV x12 2aC 1a or 1b Exp (PI +PEG/RBV) Non-cirrhotic Harvoni x12 Sof/Daclat x12 1a or 1b Exp (Sim/Sof) Non-cirrhotic Harvoni + RBV x12 1a or 1b Exp (PI +PEG/RBV) Cirrhotic Harvoni x24 Harvoni + RBV x12 Daclat/Sof +/- RBV x24 1a or 1b Exp (Sim/Sof) Cirrhotic Harvoni +RBV x24 1a or 1b Exp (NS5A inhibitor) Non-cirrhotic Defer treatment 2bC 2aB 2aB 1a or 1b Exp (NS5A inhibitor) Cirrhotic Test for NS3 PI and NS5A inhibitor resistance Tx duration x24 Add RBV 2bC AASLD/IDSA/IAS USA. Treatment Guidelines

41 Treatment Recommendations GT 2 & 3 Genotype Tx History Cirrhosis Regimen x Weeks Rating 2 Naïve Non-cirrhotic Sof + RBV x12 Daclat/Sof x12 (RBV intolerant) 2 Naïve Cirrhotic Sof + RBV x16 2bC 2 Exp (PEG/RBV) Non-cirrhotic or Cirrhotic 2 Exp (Sof + RBV) Non-cirrhotic or Cirrhotic 3 Naïve Non-cirrhotic Or Cirrhotic Sof + RBV x16 or x24 Sof + PEG/RBV x 12 Daclat/Sof +/- RBV x24 (IFN ineligible) Sof + PEG/RBV x12 Daclat/Sof +/- RBV x12 (non-cirrhotic) Daclat/Sof +/- RBV x24 (cirrhotic) Sof + PEG/RBV x 12 Sof + RBV x24 (IFN ineligible) 3 Exp (PEG/RBV) Non-cirrhotic Daclat/Sof x12 3 Exp (PEG/RBV) Cirrhotic Daclat/Sof + RBV x24 Sof + PEG/RBV x12 3 Exp (Sof + RBV) Daclat/Sof + RBV x24 (IFN ineligible) Sof + PEG/RBV x12 AASLD/IDSA/IAS USA. Treatment Guidelines aB 2aB 2aC 2aC 2aC 2aC 2aC 2aC

42 Treatment Recommendations GT 4 & 5/6 Genotype Tx History Cirrhosis Regimen x Weeks Rating 4 Naïve Non-cirrhotic or Cirrhotic 4 Exp (PEG/RBV) Non-cirrhotic or Cirrhotic 5,6 Naïve Non-cirrhotic or Cirrhotic Harvoni x12 Technivie + RBV x12 Sof + RBV x24 Sof + PEG/RBV x12 Harvoni x12 Technivie + RBV x12 Sof +PEG/RBV x12 Sof + RBV x24 Harvoni x12 Sof + PEG/RBV x12 5,6 Exp (PEG/RBV) Harvoni x12 Sof + PEG/RBV x12 2bB 1B 2aB 2B 2aB 2aB 2aB 2aB 2aB 2aB 2aC 2aC AASLD/IDSA/IAS USA. Treatment Guidelines

43 Choosing Treatment Patient specific Intolerances/allergies Baseline labs (RBV or interferon ineligible) Concomitant medications Cost/Insurance AWP (28 day supply) Daklinza $25,200 Harvoni $37,800 Olysio $26,544 Sovaldi $33,600 Technivie $30,661 Viekira Pak $33,328 Red Book Online (electronic version). 10/30/2015

44 Direct Acting Antiviral Drug Interactions (not fully inclusive) Daclatasvir Ledipasvir Viekira Simeprevir Sofosbuvir Acid Reducers X X Alfuzosin X Amiodarone X X X X X Anticonvulsants X X X X X Azole antifungals X X X Suboxone X Calcium channel blockers X X X Digoxin X X X Ethinyl estradiol X Furosemide X Gemfibrozil X Glucocorticoids X X (inhaled) X Macrolides X X Milk Thistle X PDE 5 inhibitors X X Rifampin X X X X X Salmeterol X Sedatives X X St. John s wort X X X X X Statins X X X X Adapted from: AASLD/IDSA/IAS USA. Treatment Guidelines

45 Hepatitis C Resources AASLD/IDSA Guidelines University of Liverpool, Hepatitis C drug interactions - VA Hepatitis C Information for patients and providers University of Washington, Hepatitis C online

46 References AASLD/IDSA/IAS USA. Recommendations for testing, managing, and treating hepatitis C. Accessed 10/08/15. Advances in Medications to Treat Hepatitis C. Updated September Retrieved from: Accessed 11/01/15. CDC. Testing for HCV infections: An update of guidance for clinicians and laboratories. MMWR. 2013: 62(18) Daklinza [package insert]. Princeton, NJ. Bristol-Myers Squibb Company Harvoni [package insert]. Foster City, CA: Gilead Sciences Hepatitis C FAQs for Health Professionals. Updated Oct 14, Retrieved from: Accessed 10/31/15. Hepatitis C Online: Ribavirin Drug Summary Accessed Nov 1, Hepatitis C Online: Ribavirin Drug Summary Accessed Nov 1, Hepatitis C Online: Hepatitis C Online: Peginterferon alpha-2a Drug Summary Accessed Nov 1, 2015.

47 References Hepatitis C Online: Hepatitis C Online: Peginterferon alpha-2b Drug Summary Accessed Nov 1, Lam BP, Jeffers T, Younoszai Z, et al The changing landscape of Hepatitis C virus therapy: focus on interferon-free treatment. Ther Adv Gastroenterol. 8(5) Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. (2014). Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomized study. Lancet. 394 (9956) Mandal A. Hepatitis C History. Updated April 26, Retrieved from: Accessed 11/01/15 Messina JP, Humphreys I, Flaxman A, et al Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 61(1) Olysio [package insert]. Titusville, NJ: Jansen Therapeutics Sovaldi [package insert]. Foster City, CA: Gilead Sciences Red Book Online (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: (cited: 10/30/2015). Technivie [package insert]. Chicago, IL: AbbVie Inc Viekira Pak [package insert]. Chicago, IL: AbbVie Inc

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON

More information

PHARMACY PRIOR AUTHORIZATION

PHARMACY PRIOR AUTHORIZATION PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred

More information

An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD

An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015 Matthew McMahon, MD In the United States, 2.2-3.2 million people are infected with the hepatitis C virus (HCV) Half unaware

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements

More information

Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary

Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx

More information

Request for Prior Authorization HEPATITIS C TREATMENTS

Request for Prior Authorization HEPATITIS C TREATMENTS IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax

More information

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with

More information

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio

More information

CPE Session 4. Recent Advances in the Journey to Cure Hepatitis C

CPE Session 4. Recent Advances in the Journey to Cure Hepatitis C CPE Session 4 Recent Advances in the Journey to Cure Hepatitis C Friday, April 24, 2015 ACPE UAN 0128-0000-15-024-L01-P 1.0 CPE Hour Jennifer Hickman, PharmD, BCACP Dr. Jennifer Hickman is an ambulatory

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through

More information

Objectives. Disclosures 1/26/2016. Which of These Drugs is FDA Approved for the Treatment of Genotype 1 Infection?

Objectives. Disclosures 1/26/2016. Which of These Drugs is FDA Approved for the Treatment of Genotype 1 Infection? New Horizons: Navigating the Changing Tides of Hepatitis C Therapy Jennifer Andres, PharmD, BCPS Clinical Assistant Professor of Pharmacy Practice Temple University School of Pharmacy Objectives Review

More information

Updates in Hepatitis C Treatment 2015

Updates in Hepatitis C Treatment 2015 Disclosure Updates in Hepatitis C Treatment 2015 Lindsey Childs Kean, PharmD, MPH, BCPS Clinical Assistant Professor Department of Pharmacotherapy and Translational Research University of Florida College

More information

Applicable Coding: GCN: Solvaldi - 35708; Harvoni 037179; Viekira Pak 037614; Daklinza 037073, 037074; Technivie - 037844

Applicable Coding: GCN: Solvaldi - 35708; Harvoni 037179; Viekira Pak 037614; Daklinza 037073, 037074; Technivie - 037844 Policy Subject: Policy Number: Classification: Hepatitis C Agents (new) SHS PBD38 Anti-virals: Hepatitis C Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS

More information

Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C

Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV

More information

NHS GRAMPIAN. Community Pharmacy Supply Of Hepatitis C Treatments. Pharmaceutical Care Information Pack

NHS GRAMPIAN. Community Pharmacy Supply Of Hepatitis C Treatments. Pharmaceutical Care Information Pack NHS GRAMPIAN Community Pharmacy Supply Of Hepatitis C Treatments Pharmaceutical Care Information Pack NHS Grampian Hepatology Team April 2015 NHS GRAMPIAN Community Pharmacy Supply Of Hepatitis C Treatments

More information

HEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015

HEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015 CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED

More information

Daclatasvir (Daklinza)

Daclatasvir (Daklinza) FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in

More information

A Proposal for Managing the Harvoni Wave June 22, 2015

A Proposal for Managing the Harvoni Wave June 22, 2015 A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects

More information

Update on Hepatitis C. Sally Williams MD

Update on Hepatitis C. Sally Williams MD Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;

More information

A Cure is Within Reach:

A Cure is Within Reach: A Cure is Within Reach: A Review of the New HCV Medications Misty Miller, Pharm.D., BCPS, AAHIVP Clinical Assistant Professor University of Oklahoma College of Pharmacy September 11, 2015 Pre Assessment

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following

More information

HEPATITIS C DISCUSSION GUIDE:

HEPATITIS C DISCUSSION GUIDE: HEPATITIS C DISCUSSION GUIDE: INFORMATION AND ANSWERS TO AID YOUR COUNSELING OF PATIENTS INDICATION HARVONI is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Warnings

More information

Chronic Hepatitis C Virus (Chronic HCV)

Chronic Hepatitis C Virus (Chronic HCV) Chronic Hepatitis C Virus (Chronic HCV) Amie Baumgartner PA-C Fall 2015 Purpose of Lecture! Educate Gastroenterology nurses about Hepatitis C and its treatment in order to improve their knowledge and confidence

More information

I. What s New and Updates/Changes (Last updated: February 17, 2015; last reviewed: February 17, 2015) Summary Table

I. What s New and Updates/Changes (Last updated: February 17, 2015; last reviewed: February 17, 2015) Summary Table Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health Contents I. What

More information

Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015

Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015 Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015 Drug-Drug Interactions between Direct Acting Antiviral (DAA) and Antiretroviral Therapy (ART)

More information

Treatment of Chronic Hepatitis C - September 2015 Update

Treatment of Chronic Hepatitis C - September 2015 Update Treatment of Chronic Hepatitis C - September 2015 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Beat Müllhaupt, Andri Rauch, Jan Fehr and Darius

More information

Hepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014

Hepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014 Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go

More information

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What

More information

----------------------DOSAGE FORMS AND STRENGTHS--------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION

----------------------DOSAGE FORMS AND STRENGTHS--------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLYSIO safely and effectively. See full prescribing information for OLYSIO. OLYSIO (simeprevir) capsules,

More information

PRIOR AUTHORIZATION POLICY

PRIOR AUTHORIZATION POLICY PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus

More information

UPDATE: New Hepatitis C Combination Agents

UPDATE: New Hepatitis C Combination Agents UPDATE: New Hepatitis C Combination Agents Ledipasvir and Sofosbuvir (Harvoni ) Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir (Viekira Pak ) Final Report July 2015 Review prepared by: Melissa Archer,

More information

Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015

Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015 Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015 Disclosures: In the past two years I have participated in research 1 or received consultation/speaking fees 2 from: Astellas 2 Abbvie

More information

Prior Authorization Policy

Prior Authorization Policy Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin

More information

The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection

The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection A Technology Assessment Final Report April 15, 2014 Completed by: Institute

More information

UPDATE ON NEW HEPATITIS C MEDICINES

UPDATE ON NEW HEPATITIS C MEDICINES UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir

More information

Disclosure. Pharmacy technician objectives. Pharmacist objectives. Epidemiology. Terminology 3/3/2015. Treatment of Hepatitis C

Disclosure. Pharmacy technician objectives. Pharmacist objectives. Epidemiology. Terminology 3/3/2015. Treatment of Hepatitis C Disclosure Treatment of Hepatitis C Katerina Tagaras PGY-1 Resident Palmetto General Hospital I do not have a vested interest in or affiliation with any corporate organization offering financial support

More information

The question and answer session is not available after the live webinar.

The question and answer session is not available after the live webinar. 1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments

More information

Hepatitis B: Objectives. Hepatitis C: Objectives. Hepatitis B: Natural History. Hepatitis B is a DNA virus and is NOT curable.

Hepatitis B: Objectives. Hepatitis C: Objectives. Hepatitis B: Natural History. Hepatitis B is a DNA virus and is NOT curable. Two Silent Epidemics - Chronic Hepatitis B and Hepatitis C: A Primer for Primary Care Practitioners Rebekah Hamner, MA, MSN, APRN, AGCNS Austin Hepatitis Center Dr. Imtiaz Alam 1/25/15 Hepatitis B: Objectives

More information

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment

Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment Direct-acting antiviral (DAA) drugs exhibit considerable variability in mechanisms of metabolism

More information

HCV Pipeline: The Next 18 Months Michael W. Fried, MD

HCV Pipeline: The Next 18 Months Michael W. Fried, MD HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research

More information

DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS. Ledipasvir (LDV, GS-5885) Gilead. 90 mg once daily

DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS. Ledipasvir (LDV, GS-5885) Gilead. 90 mg once daily DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS Pharmacology Adult Dose NS5A replication complex inhibitor Approved in Japan and the EU: 60 mg once daily NS5A inhibitor NS5A inhibitor

More information

Goals of Therapy. Treatment Options for Hepatitis C. Patterns of Response. Progress in Hepatitis C Therapy

Goals of Therapy. Treatment Options for Hepatitis C. Patterns of Response. Progress in Hepatitis C Therapy Treatment Options for Hepatitis C Helen S. Te, M.D. Center for Liver Diseases University of Chicago Hospitals Chicago, Illinois Primary: To eliminate the virus Goals of Therapy Secondary: To decrease inflammation

More information

Hepatitis C Antiviral Therapy

Hepatitis C Antiviral Therapy MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Hepatitis C Antiviral Therapy Number 5.01.606 Effective Date

More information

Treatment of Hepatitis C in Patients with Renal Insufficiency

Treatment of Hepatitis C in Patients with Renal Insufficiency HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,

More information

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi

More information

Hepatitis C Virus and HIV Co-infection 2015 Update. Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015

Hepatitis C Virus and HIV Co-infection 2015 Update. Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015 Hepatitis C Virus and HIV Co-infection 2015 Update Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015 1 Statement of Disclosure Presenter has no relevant financial

More information

HIV/HCV Co-Infection

HIV/HCV Co-Infection HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology

More information

HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014.

HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014. Page 1 HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014. This report summarises interaction studies relating

More information

Prior Authorization Conditions for Approval of Hepatitis C Agents

Prior Authorization Conditions for Approval of Hepatitis C Agents Prior Authorization Conditions for Approval of Hepatitis C Agents All requests for Hepatitis C Agents require a prior authorization and will be screened for medical necessity and appropriateness using

More information

Debate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities

Debate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology

More information

Learning Objectives. HCV Treatment Evolution. Evolution of HCV Therapy 4/7/2014. Hepatitis C: A health problem of global importance!

Learning Objectives. HCV Treatment Evolution. Evolution of HCV Therapy 4/7/2014. Hepatitis C: A health problem of global importance! Therapy New HCV In Frontiers We have no conflict of interest to declare. How the Magic Pill Cured Hep C Spring Therapeutics Update Trana Hussaini, Pharm D Nilu Partovi, Pharm D Google Images; collage by

More information

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n

More information

Hepatitis C Virus (HCV)

Hepatitis C Virus (HCV) HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median

More information

Viral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines

Viral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts

More information

Review: How to work up your patient with Hepatitis C

Review: How to work up your patient with Hepatitis C Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.

More information

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Hepatitis C in 2015. Primary Care Providers: Linkage to Care

Hepatitis C in 2015. Primary Care Providers: Linkage to Care Hepatitis C in 2015 Primary Care Providers: Linkage to Care Michael D Voigt Medical Director, Liver Failure and Transplantation University of Iowa, Hospitals and Clinics Disclosures I have NO disclosures

More information

Current & New Hepatitis C Meds on the Horizon

Current & New Hepatitis C Meds on the Horizon Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated

More information

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052) Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).

More information

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2015. All rights reserved.

More information

DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME

DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28

More information

Objectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening

Objectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to

More information

The Rapid Evolution of Treatment Strategies for Hepatitis C

The Rapid Evolution of Treatment Strategies for Hepatitis C CLINICAL AND SYSTEMATIC S nature publishing group 1 see related editorial on page x The Rapid Evolution of Treatment Strategies for Hepatitis C Andrew J. Muir, MD, MHS1 Hepatitis C virus (HCV) treatment

More information

HEPATITIS C TREATMENT GUIDELINES

HEPATITIS C TREATMENT GUIDELINES HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete

More information

Susan Kidger. North Manchester General Hospital. 16 th Annual Conference of the National HIV Nurses Association (NHIVNA)

Susan Kidger. North Manchester General Hospital. 16 th Annual Conference of the National HIV Nurses Association (NHIVNA) 16 th Annual Conference of the National HIV Nurses Association (NHIVNA) Susan Kidger North Manchester General Hospital 26-27 June 2014- City Hall, Cardiff 2 nd Generation Treatment for Hepatitis C and

More information

DOSAGE FORMS AND STRENGTHS Tablets: Ombitasvir, paritaprevir, ritonavir: 12.5/75/50 mg (3) Dasabuvir: 250 mg (3)

DOSAGE FORMS AND STRENGTHS Tablets: Ombitasvir, paritaprevir, ritonavir: 12.5/75/50 mg (3) Dasabuvir: 250 mg (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VIEKIRA PAK safely and effectively. See full prescribing information for VIEKIRA PAK. VIEKIRA PAK

More information

Treatment of Chronic Hepatitis C - September 2014 Update

Treatment of Chronic Hepatitis C - September 2014 Update Treatment of Chronic Hepatitis C - September 014 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Darius Moradpour, Andri Rauch, Jan Fehr and Beat

More information

Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C

Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014

More information

Current Opinion in Hepatitis C Treatment

Current Opinion in Hepatitis C Treatment White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University

More information

New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C

New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during

More information

Transmission of HCV in the United States (CDC estimate)

Transmission of HCV in the United States (CDC estimate) Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong

More information

An Action Guide for the Treatment of Chronic Hepatitis C Infection: Next Steps for Patients

An Action Guide for the Treatment of Chronic Hepatitis C Infection: Next Steps for Patients The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection An Action Guide for the Treatment of Chronic Hepatitis C Infection: Next

More information

Hepatitis C: Increasing Access and Improving Cure Rates

Hepatitis C: Increasing Access and Improving Cure Rates Hepatitis C: Increasing Access and Improving Cure Rates David Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine 1 Disclosures The planners and presenter have disclosed

More information

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012 Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public

More information

Treating Chronic Hepatitis C. A Review of the Research for Adults

Treating Chronic Hepatitis C. A Review of the Research for Adults Treating Chronic Hepatitis C A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have chronic hepatitis C.

More information

New IDSA/AASLD Guidelines for Hepatitis C

New IDSA/AASLD Guidelines for Hepatitis C NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation

More information

HEPATITIS C UPDATE: A Quarter-Century Dramatic Journey. Steve T. Chen M.D. FACP, FACG

HEPATITIS C UPDATE: A Quarter-Century Dramatic Journey. Steve T. Chen M.D. FACP, FACG HEPATITIS C UPDATE: A Quarter-Century Dramatic Journey Steve T. Chen M.D. FACP, FACG Hepatitis C Virus: Morphology and Characteristics Hepatitis C Virus Discovered in 1989 Nucleic Acid: 9.6 kb ssrna 40-60

More information

Chronische Hepatitis C. 170 Millionen

Chronische Hepatitis C. 170 Millionen Chronische Hepatitis C 170 Millionen Natürliche Geschichte der Hepatitis C Akute Hepatitis C Chronische Hepatitis C Hepatitis Zirrhose Clearance Zeit (20 Jahre) ist sehr unterschiedlich (Host, Virus, Umwelt)

More information

HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014

HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HARVONI safely and effectively. See full prescribing information for HARVONI. HARVONI (ledipasvir

More information

Eradicating HCV: Opportunities and Challenges

Eradicating HCV: Opportunities and Challenges Eradicating HCV: Opportunities and Challenges Andrew Reynolds Hepatitis C Education Manager Project inform Disclosures and a Confession Disclosure I have no financial relationships to disclose and I will

More information

Daclatasvir for treating chronic hepatitis C

Daclatasvir for treating chronic hepatitis C NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Appraisal consultation document Daclatasvir for treating chronic hepatitis C The Department of Health has asked the National Institute for Health and Care

More information

Drug Interactions in HIV/HCV coinfection

Drug Interactions in HIV/HCV coinfection HIV/HCV Drug Interactions Case Based Discussion John J. Faragon, PharmD, BCPS, AAHIVP Regional Pharmacy Director, NY/NJ AETC HIV Pharmacist, Albany Medical Center 1 Drug Interactions in HIV/HCV coinfection

More information

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir

More information

Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement

Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C; Prabhu Gounder,

More information

GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF

GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR

More information

APASL consensus statements and recommendation on treatment of hepatitis C

APASL consensus statements and recommendation on treatment of hepatitis C DOI 10.1007/s12072-016-9717-6 GUIDELINES APASL consensus statements and recommendation on treatment of hepatitis C Masao Omata 1,2 Tatsuo Kanda 3 Lai Wei 4 Ming-Lung Yu 5 Wang-Long Chuang 6 Alaaeldin Ibrahim

More information

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

Disclosure of Conflicts of Interest Learner Assurance Statement:

Disclosure of Conflicts of Interest Learner Assurance Statement: Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation

More information

Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP

Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of

More information

All hepatitis C medications are specialty products; dispensing is available only via BriovaRx specialty pharmacy.

All hepatitis C medications are specialty products; dispensing is available only via BriovaRx specialty pharmacy. Hepatitis C Medications Prior Authorization Criteria Harvoni (ledipasvir/sofosbuvir), Sovaldi (sofosbuvir), Olysio (simeprevir) #, pegylated interferon (Pegasys & Peg-Intron ), Viekira Pak (ombitasvir/paritaprevir/ritonavir;

More information

CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report

CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report Product Line: Therapeutic Review Version: 1.0 Volume Number: 3 Issue Number: 1d Publication Date: November 2015

More information

Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015

Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015 June 215 Volume 11, Issue 6, Supplement 3 A SPECIAL MEETING REVIEW EDITION Advances in the Treatment of Hepatitis C Virus Infection From EASL 215 The 5th Annual Meeting of the European Association for

More information

Back to main HCV Drug Development Section. December 2012. By Tracy Swan

Back to main HCV Drug Development Section. December 2012. By Tracy Swan Submitted by tracyswan on Wed, 12/12/2012-20:09 Back to main HCV Drug Development Section December 2012 By Tracy Swan It is difficult to be anything other than dazzled by astounding cure rates of up to

More information

Provision of Clinical Pharmacist Services for Individuals With Chronic Hepatitis C Viral Infection

Provision of Clinical Pharmacist Services for Individuals With Chronic Hepatitis C Viral Infection PRN OPINION P APER Provision of Clinical Pharmacist Services for Individuals With Chronic Hepatitis C Viral Infection Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,

More information

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive

More information